Biohit OyjLTS:0DRP +4.01%78 PS Ratio is 2.76 as of Jul. 08, 2026, which is 24% below its 10-year median of 3.64. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.70 (Fairly Valued). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Biohit Oyj ranks better than 53.11% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Biohit Oyj's share price is €2.85.
Biohit Oyj's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.03. Hence, Biohit Oyj's PS Ratio for today is 2.76.
The historical rank and industry rank for Biohit Oyj's PS Ratio or its related term are showing as below:
LTS:0DRP'
s PS Ratio Range Over the Past 10 Years
Min: 1.76 Med: 3.64 Max: 14.71
Current: 2.74
During the past 13 years, Biohit Oyj's highest PS Ratio was 14.71. The lowest was 1.76. And the median was 3.64.
LTS:0DRP's PS Ratio is ranked better than 53.11% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.935
vs LTS:0DRP: 2.74
During the past 12 months, the average Revenue per Share Growth Rate of Biohit Oyj was 8.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.50% per year.
During the past 13 years, Biohit Oyj's highest 3-Year average Revenue per Share Growth Rate was 40.00% per year. The lowest was -62.00% per year. And the median was 7.20% per year.
Back to Basics: PS Ratio
Biohit Oyj (LTS:0DRP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Biohit Oyj PS Ratio Related Terms
Biohit Oyj PS Ratio Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's PS Ratio distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Biohit Oyj's Share Price of today is €2.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Biohit Oyj (LTS:0DRP) has a PS Ratio of 2.76 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Biohit Oyj and its competitors. This is 24% below median its historical median of 3.64. Over the past decade, Biohit Oyj's PS Ratio has ranged from 1.76 to 14.71. According to the industry distribution chart, Biohit Oyj ranks #377 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 46.9%.
Is Biohit Oyj's PS Ratio too high?
Biohit Oyj's current PS Ratio of 2.76 is 24% below median its 10-year median of 3.64. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 14.71. The Medical Devices & Instruments industry median PS Ratio is 2.94. Biohit Oyj's value of 2.76 is 6% below this industry median. Based on the distribution chart, Biohit Oyj ranks #377 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #377 out of 804 companies for PS Ratio. This puts Biohit Oyj in the upper half of its industry. The industry median PS Ratio is 2.94. Biohit Oyj's value of 2.76 is 6% below this benchmark. Historically, Biohit Oyj's own PS Ratio has ranged from 1.76 to 14.71 over the past decade. While the company's 10-year median is 3.64 vs. the industry median of 2.94, Biohit Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current PS Ratio of 2.76 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current PS Ratio is 2.76, which is 24% below median its own 10-year median of 3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.85 — trading 5.6% above its estimated fair value. The current PS Ratio is 2.76, which is 24% below median its 10-year median of 3.64 and 6% below the Medical Devices & Instruments industry median of 2.94. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current PS Ratio is 2.76 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.85 is trading 5.6% above its estimated GF Value™ of €2.70.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
PS Ratio: 2.76 (24% below median its 10-year median of 3.64)
GF Value™: €2.70 vs. price of €2.85 (5.6% above fair value)
Industry Position: 6% below the Medical Devices & Instruments median (#377 of 804)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
